Laura Baumgartner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Baumgartner has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Amanda Morris
Touro University California, College of Pharmacy, Vallejo, California
4 shared publications- Amanda Morris
Department of Pharmaceutical Services, University of California, San Francisco Medical Center, San Francisco, USA
2 shared publications - Adalyn Schuenemeyer
Montezuma Orchard Restoration Project
1 shared publication Amanda A. Morris
University of California San Francisco Medical Center, San Francisco, CA, USA
1 shared publication- Amelia Brackett Hogstad
University of Colorado
1 shared publication - Amy Dunbar-Wallis
Department of Ecology and Evolutionary Biology, University of Colorado, Boulder, USA
1 shared publication
Latest Publications
- 1 November 2022
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 86 (8)
Burnout Among Pharmacy Preceptors in Northern California
Objective. The objective of this study was to investigate the incidence of burnout syndrome among pharmacy preceptors, and to identify predictors for the development of burnout among this population. Methods. This cross-sectional survey study examined burnout syndrome among pharmacy preceptors in Northern California. Preceptors were included if they self-identified as a preceptor to Advanced Pharmacy Practice Experience (APPE) students and Pharmacy Graduate Year One (PGY-1) residents. Burnout was assessed using the MBI-HSS, and preceptors were classified as having burnout syndrome if they scored high on emotional exhaustion (EE) plus either high on depersonalization (DP) or low on personal accomplishment (PA). Additionally, demographics, workplace environment, workload, and day-to-day workflow were queried to help determine predictors of burnout syndrome among this population. Result. One hundred and thirteen pharmacy preceptors were included in the study. Twenty two percent of preceptors reported scores consistent with burnout, with 57% of preceptors scoring positive for burnout in one of the three burnout criteria. On multivariate regression analysis, two independent risk factors for burnout syndrome were identified; preceptors who precepted a large number of difficult or unmotivated learners per year, and preceptors who did not feel their contributions as preceptors were appreciated by their institution. Conclusion. The rate of burnout among pharmacy preceptors is high, with preceptors exhibiting high EE and low levels of PA. Precepting a large number of difficult or unmotivated learners, and not feeling contributions as preceptors are appreciated, appear to be predictors of burnout syndrome.
- 1 November 2022
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 86 (8)
Burnout Among Pharmacy Preceptors in Northern California
Objective. The objective of this study was to investigate the incidence of burnout syndrome among pharmacy preceptors, and to identify predictors for the development of burnout among this population. Methods. This cross-sectional survey study examined burnout syndrome among pharmacy preceptors in Northern California. Preceptors were included if they self-identified as a preceptor to Advanced Pharmacy Practice Experience (APPE) students and Pharmacy Graduate Year One (PGY-1) residents. Burnout was assessed using the MBI-HSS, and preceptors were classified as having burnout syndrome if they scored high on emotional exhaustion (EE) plus either high on depersonalization (DP) or low on personal accomplishment (PA). Additionally, demographics, workplace environment, workload, and day-to-day workflow were queried to help determine predictors of burnout syndrome among this population. Result. One hundred and thirteen pharmacy preceptors were included in the study. Twenty two percent of preceptors reported scores consistent with burnout, with 57% of preceptors scoring positive for burnout in one of the three burnout criteria. On multivariate regression analysis, two independent risk factors for burnout syndrome were identified; preceptors who precepted a large number of difficult or unmotivated learners per year, and preceptors who did not feel their contributions as preceptors were appreciated by their institution. Conclusion. The rate of burnout among pharmacy preceptors is high, with preceptors exhibiting high EE and low levels of PA. Precepting a large number of difficult or unmotivated learners, and not feeling contributions as preceptors are appreciated, appear to be predictors of burnout syndrome.
- 19 July 2022
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 76, 102146
Evaluation of intrapleural fibrinolytic therapy and dosing strategies used for complicated pleural effusions
- 19 July 2022
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 76, 102146
Evaluation of intrapleural fibrinolytic therapy and dosing strategies used for complicated pleural effusions
- 1 December 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 13 (12) , 1572-1577
Performance on advanced pharmacy practice experiences after implementation of mock acute care patient simulations
- 1 December 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 13 (12) , 1572-1577
Performance on advanced pharmacy practice experiences after implementation of mock acute care patient simulations
- Open Access
- 8 September 2021
- Published by Springer Nature in Neurocritical Care
- Vol. 36 (2) , 511-518
Pre Versus Post Implementation of a Pharmacologic Antishivering Protocol During Targeted Temperature Management Following Cardiac Arrest
Background: Targeted temperature management (TTM) is endorsed by various guidelines to improve neurologic outcomes following cardiac arrest. Shivering, a consequence of hypothermia, can counteract the benefits of TTM. Despite its frequent occurrence, consensus guidelines provide minimal guidance on the management of shivering. The purpose of this study was to evaluate the impact of a pharmacologic antishivering protocol in patients undergoing TTM following cardiac arrest on the incidence of shivering. Methods: A retrospective observational cohort study at a large academic medical center of adult patients who underwent TTM targeting 33 °C following out-of-hospital (OHCA) or in-hospital cardiac arrest (IHCA) was conducted between January 2013 and January 2019. Patients were included in the preprotocol group if they received TTM prior to the initiation of a pharmacologic antishivering protocol in 2015. The primary outcome was incidence of shivering between pre- and postprotocol patients. Secondary outcomes included time from arrest (IHCA) or admission to the hospital (OHCA) to goal body temperature, total time spent at goal body temperature, and percentage of patients alive at discharge. All pharmacologic agents listed as part of the antishivering protocol were recorded. Results: Fifty-one patients were included in the preprotocol group, and 80 patients were included in the postprotocol group. There were no significant differences in baseline characteristics between the groups, including percentage of patients experiencing OHCA (75% vs. 63%, p = 0.15) and time from arrest to return of spontaneous circulation (17.5 vs. 17.9 min, p = 0.96). Incidence of patients with shivering was significantly reduced in the postprotocol group (57% vs. 39%, p = 0.03). Time from arrest (IHCA) or admission to the hospital (OHCA) to goal body temperature was similar in both groups (5.1 vs. 5.3 h, p = 0.57), in addition to total time spent at goal body temperature (17.7 vs. 18 h, p = 0.93). The percentage of patients alive at discharge was significantly improved in the postprotocol group (35% vs. 55%, p = 0.02). Patients in the postprotocol group received significantly more buspirone (4% vs. 73%, p < 0.01), meperidine (8% vs. 34%, p < 0.01), and acetaminophen (12% vs. 65%, p < 0.01) as part of the pharmacologic antishivering protocol. Use of neuromuscular blockade significantly decreased post protocol (19% vs. 6%, p = 0.02). Conclusions: In patients undergoing TTM following cardiac arrest, the implementation of a pharmacologic antishivering protocol reduced the incidence of shivering and the use neuromuscular blocking agents. Prospective data are needed to validate the results and further evaluate the safety and efficacy of an antishivering protocol on clinical outcomes.
- 8 September 2021
- Published by Springer Nature in Neurocritical Care
- Vol. 36 (2) , 511-518
Open AccessPre Versus Post Implementation of a Pharmacologic Antishivering Protocol During Targeted Temperature Management Following Cardiac Arrest
Background: Targeted temperature management (TTM) is endorsed by various guidelines to improve neurologic outcomes following cardiac arrest. Shivering, a consequence of hypothermia, can counteract the benefits of TTM. Despite its frequent occurrence, consensus guidelines provide minimal guidance on the management of shivering. The purpose of this study was to evaluate the impact of a pharmacologic antishivering protocol in patients undergoing TTM following cardiac arrest on the incidence of shivering. Methods: A retrospective observational cohort study at a large academic medical center of adult patients who underwent TTM targeting 33 °C following out-of-hospital (OHCA) or in-hospital cardiac arrest (IHCA) was conducted between January 2013 and January 2019. Patients were included in the preprotocol group if they received TTM prior to the initiation of a pharmacologic antishivering protocol in 2015. The primary outcome was incidence of shivering between pre- and postprotocol patients. Secondary outcomes included time from arrest (IHCA) or admission to the hospital (OHCA) to goal body temperature, total time spent at goal body temperature, and percentage of patients alive at discharge. All pharmacologic agents listed as part of the antishivering protocol were recorded. Results: Fifty-one patients were included in the preprotocol group, and 80 patients were included in the postprotocol group. There were no significant differences in baseline characteristics between the groups, including percentage of patients experiencing OHCA (75% vs. 63%, p = 0.15) and time from arrest to return of spontaneous circulation (17.5 vs. 17.9 min, p = 0.96). Incidence of patients with shivering was significantly reduced in the postprotocol group (57% vs. 39%, p = 0.03). Time from arrest (IHCA) or admission to the hospital (OHCA) to goal body temperature was similar in both groups (5.1 vs. 5.3 h, p = 0.57), in addition to total time spent at goal body temperature (17.7 vs. 18 h, p = 0.93). The percentage of patients alive at discharge was significantly improved in the postprotocol group (35% vs. 55%, p = 0.02). Patients in the postprotocol group received significantly more buspirone (4% vs. 73%, p < 0.01), meperidine (8% vs. 34%, p < 0.01), and acetaminophen (12% vs. 65%, p < 0.01) as part of the pharmacologic antishivering protocol. Use of neuromuscular blockade significantly decreased post protocol (19% vs. 6%, p = 0.02). Conclusions: In patients undergoing TTM following cardiac arrest, the implementation of a pharmacologic antishivering protocol reduced the incidence of shivering and the use neuromuscular blocking agents. Prospective data are needed to validate the results and further evaluate the safety and efficacy of an antishivering protocol on clinical outcomes.
- Open Access
- 3 February 2021
- Published by Ubiquity Press, Ltd. in Citizen Science: Theory and Practice
- Vol. 6 (1) , 25
Creating Study-Specific Tools to Increase Community and Student Engagement
- 3 February 2021
- Published by Ubiquity Press, Ltd. in Citizen Science: Theory and Practice
- Vol. 6 (1) , 25
Open AccessCreating Study-Specific Tools to Increase Community and Student Engagement
- 1 October 2019
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 11 (10) , 1016-1021
High-fidelity simulation increases pharmacy resident perceived competence during medical emergencies
- 1 October 2019
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 11 (10) , 1016-1021
High-fidelity simulation increases pharmacy resident perceived competence during medical emergencies
- 1 February 2019
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 53 (7) , 705-710
Impact of Quetiapine Therapy on QTc Prolongation in Critically Ill Patients
Background: Quetiapine is an atypical antipsychotic commonly utilized for the management of delirium in critically ill patients. The impact of quetiapine on QTc in the critically ill population is largely unknown. Objective: The purpose of this study was to evaluate QTc prolongation following administration of quetiapine for the management of delirium in critically ill patients. Methods: This was a single-center prospective, observational cohort study. QTc measurements of patients who received at least one dose of quetiapine were compared with a control group receiving melatonin. The primary outcome was mean change in QTc from baseline to maximum serum drug concentration after the first dose of quetiapine. Results: No significant change in QTc was observed from baseline to post–quetiapine administration, with a mean change in QTc of 2.7 ms (438.4 ± 43.2 ms vs 441.1 ± 36.4 ms; P = 0.50). When comparing mean change in QTc between the quetiapine group and melatonin group, the difference was not significant (2.7 ± 37.8 ms vs −0.18 ± 32.0 ms, P = 0.73). Conclusion and Relevance: This study represents one of the first prospective studies evaluating the impact of quetiapine on QTc. The results of this study demonstrate a nonsignificant statistical and clinical change in the QTc following quetiapine administration in critically ill patients utilizing telemetry measurements. Routine QTc monitoring with formal electrocardiogram(s) following quetiapine administration may not be warranted.
- 1 February 2019
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 53 (7) , 705-710
Impact of Quetiapine Therapy on QTc Prolongation in Critically Ill Patients
Background: Quetiapine is an atypical antipsychotic commonly utilized for the management of delirium in critically ill patients. The impact of quetiapine on QTc in the critically ill population is largely unknown. Objective: The purpose of this study was to evaluate QTc prolongation following administration of quetiapine for the management of delirium in critically ill patients. Methods: This was a single-center prospective, observational cohort study. QTc measurements of patients who received at least one dose of quetiapine were compared with a control group receiving melatonin. The primary outcome was mean change in QTc from baseline to maximum serum drug concentration after the first dose of quetiapine. Results: No significant change in QTc was observed from baseline to post–quetiapine administration, with a mean change in QTc of 2.7 ms (438.4 ± 43.2 ms vs 441.1 ± 36.4 ms; P = 0.50). When comparing mean change in QTc between the quetiapine group and melatonin group, the difference was not significant (2.7 ± 37.8 ms vs −0.18 ± 32.0 ms, P = 0.73). Conclusion and Relevance: This study represents one of the first prospective studies evaluating the impact of quetiapine on QTc. The results of this study demonstrate a nonsignificant statistical and clinical change in the QTc following quetiapine administration in critically ill patients utilizing telemetry measurements. Routine QTc monitoring with formal electrocardiogram(s) following quetiapine administration may not be warranted.
- 21 January 2019
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 39 (3) , 280-287
Effectiveness of Melatonin for the Prevention of Intensive Care Unit Delirium
Study Objective: Intensive care unit (ICU) delirium is an acute brain dysfunction that has been associated with increased mortality, prolonged ICU and hospital lengths of stay, and development of post‐ICU cognitive impairment. Melatonin may help to restore sleep and reduce the occurrence of ICU delirium. The purpose of this study was to evaluate the effectiveness of melatonin for the prevention of ICU delirium in critically ill adults.Design: Retrospective, observational cohort study.Setting: Large academic medical center.Patients: A total of 232 adults were included who were admitted to the medical‐surgical or cardiac ICUs between 2013 and 2017 who had a negative Confusion Assessment Method for the ICU (CAM‐ICU). Of those, patients who received melatonin for at least 48 hours were included in the melatonin group (n=117). Patients were included in the control group if they were admitted to the ICU for at least 4 days (average time of melatonin initiation) and did not receive melatonin or antipsychotics within the first 4 days of their ICU stay (n=115).Measurements and Main Results: The primary outcome was development of delirium, which was assessed by using the CAM‐ICU twice daily by nursing staff. The development of delirium was significantly lower in the melatonin group: 9 (7.7%) versus 28 (24.3%) patients (p = 0.001). This finding remained significant in multivariate logistic models controlling for age, sex, history of hypertension, need for emergent surgery, Acute Physiology and Chronic Health Evaluation II score, mechanical ventilation, ICU length of stay, dexmedetomidine use, and benzodiazepine use. For those patients who developed delirium, patients in the control group had, on average, 20.9 delirium‐free days without coma in 28 days compared with 19.9 days in the melatonin group (p = 0.72). In the melatonin group, melatonin was used for a mean ± SD of 6.3 ± 7.9 days, with a median dose of 3.5 mg/night (range: 1–10 mg).Conclusion: The development of ICU delirium was significantly lower in the melatonin group compared with that in the control group. To our knowledge, this is one of the only studies that has examined the use of melatonin for the prevention of ICU delirium. Melatonin may be a promising agent for the prevention of ICU delirium; however, a randomized study is needed to further validate its efficacy.
- 21 January 2019
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 39 (3) , 280-287
Effectiveness of Melatonin for the Prevention of Intensive Care Unit Delirium
Study Objective: Intensive care unit (ICU) delirium is an acute brain dysfunction that has been associated with increased mortality, prolonged ICU and hospital lengths of stay, and development of post‐ICU cognitive impairment. Melatonin may help to restore sleep and reduce the occurrence of ICU delirium. The purpose of this study was to evaluate the effectiveness of melatonin for the prevention of ICU delirium in critically ill adults.Design: Retrospective, observational cohort study.Setting: Large academic medical center.Patients: A total of 232 adults were included who were admitted to the medical‐surgical or cardiac ICUs between 2013 and 2017 who had a negative Confusion Assessment Method for the ICU (CAM‐ICU). Of those, patients who received melatonin for at least 48 hours were included in the melatonin group (n=117). Patients were included in the control group if they were admitted to the ICU for at least 4 days (average time of melatonin initiation) and did not receive melatonin or antipsychotics within the first 4 days of their ICU stay (n=115).Measurements and Main Results: The primary outcome was development of delirium, which was assessed by using the CAM‐ICU twice daily by nursing staff. The development of delirium was significantly lower in the melatonin group: 9 (7.7%) versus 28 (24.3%) patients (p = 0.001). This finding remained significant in multivariate logistic models controlling for age, sex, history of hypertension, need for emergent surgery, Acute Physiology and Chronic Health Evaluation II score, mechanical ventilation, ICU length of stay, dexmedetomidine use, and benzodiazepine use. For those patients who developed delirium, patients in the control group had, on average, 20.9 delirium‐free days without coma in 28 days compared with 19.9 days in the melatonin group (p = 0.72). In the melatonin group, melatonin was used for a mean ± SD of 6.3 ± 7.9 days, with a median dose of 3.5 mg/night (range: 1–10 mg).Conclusion: The development of ICU delirium was significantly lower in the melatonin group compared with that in the control group. To our knowledge, this is one of the only studies that has examined the use of melatonin for the prevention of ICU delirium. Melatonin may be a promising agent for the prevention of ICU delirium; however, a randomized study is needed to further validate its efficacy.
- 6 September 2018
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 33 (3) , 262-266
Reduced Versus Conventional Dose Insulin for Hyperkalemia Treatment
Using a reduced dose of 5 units of regular insulin has been proposed as a strategy to mitigate the risk of hypoglycemia when treating hyperkalemia. The comparative efficacy and safety of this strategy to conventional 10 units is not well established. To compare the effectiveness of reduced and conventional dosed insulin for hyperkalemia treatment. Electronic medication administration reports of conventional or reduced doses of insulin given for hyperkalemia treatment were reviewed from July 2013 to September 2015. The primary outcome was reduction in serum potassium. Ninety-two administrations of reduced dose insulin and 309 administrations of conventional dose insulin were included. No significant difference was found in potassium reduction between the groups (−0.096 mmol/L, P value = .2210). Post hoc subgroup analysis of patients with serum potassium > 6 mmol/L revealed a lower reduction in potassium in the reduced dose group compared to the conventional dose group (difference: −0.238 mmol/L, P value = .018). Conventional dose insulin may be more effective than reduced dose regular insulin at baseline serum potassium levels >6 mmol/L in the treatment of hyperkalemia. Frequent monitoring of serum potassium and glucose after administration of insulin is necessary to confirm adequate response and avoidance of hypoglycemia.
- 6 September 2018
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 33 (3) , 262-266
Reduced Versus Conventional Dose Insulin for Hyperkalemia Treatment
Using a reduced dose of 5 units of regular insulin has been proposed as a strategy to mitigate the risk of hypoglycemia when treating hyperkalemia. The comparative efficacy and safety of this strategy to conventional 10 units is not well established. To compare the effectiveness of reduced and conventional dosed insulin for hyperkalemia treatment. Electronic medication administration reports of conventional or reduced doses of insulin given for hyperkalemia treatment were reviewed from July 2013 to September 2015. The primary outcome was reduction in serum potassium. Ninety-two administrations of reduced dose insulin and 309 administrations of conventional dose insulin were included. No significant difference was found in potassium reduction between the groups (−0.096 mmol/L, P value = .2210). Post hoc subgroup analysis of patients with serum potassium > 6 mmol/L revealed a lower reduction in potassium in the reduced dose group compared to the conventional dose group (difference: −0.238 mmol/L, P value = .018). Conventional dose insulin may be more effective than reduced dose regular insulin at baseline serum potassium levels >6 mmol/L in the treatment of hyperkalemia. Frequent monitoring of serum potassium and glucose after administration of insulin is necessary to confirm adequate response and avoidance of hypoglycemia.
- 14 September 2016
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 30 (6) , 650-652
Hypersensitivity Reaction Following Administration of Low-Dose Oral Vancomycin for the Treatment of Clostridium difficile in a Patient With Normal Renal Function
Systemic absorption of oral vancomycin for the treatment of Clostridium difficile is thought to be trivial in patients without risk factors for increased systemic absorption and is often overlooked in clinical practice. A 51-year-old male elicits a suspected immunoglobulin E-mediated hypersensitivity following administration of low-dose oral vancomycin for the treatment of severe C difficile. The patient had normal renal function and was administered low doses of the medication, however, had a medical history significant for diverticulitis. Applying the Naranjo adverse drug reaction probability scale, a score of 5 was obtained, indicating a probable association between the administration of oral vancomycin and the hypersensitivity reaction. This case demonstrates that hypersensitivity reactions following low-dose oral vancomycin administration in patients with severe C difficile are possible, despite having normal renal function. Other risk factors for systemic absorption of oral vancomycin need to be evaluated in the literature, including severity of disease and underlying gastrointestinal processes.
- 14 September 2016
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 30 (6) , 650-652
Hypersensitivity Reaction Following Administration of Low-Dose Oral Vancomycin for the Treatment of Clostridium difficile in a Patient With Normal Renal Function
Systemic absorption of oral vancomycin for the treatment of Clostridium difficile is thought to be trivial in patients without risk factors for increased systemic absorption and is often overlooked in clinical practice. A 51-year-old male elicits a suspected immunoglobulin E-mediated hypersensitivity following administration of low-dose oral vancomycin for the treatment of severe C difficile. The patient had normal renal function and was administered low doses of the medication, however, had a medical history significant for diverticulitis. Applying the Naranjo adverse drug reaction probability scale, a score of 5 was obtained, indicating a probable association between the administration of oral vancomycin and the hypersensitivity reaction. This case demonstrates that hypersensitivity reactions following low-dose oral vancomycin administration in patients with severe C difficile are possible, despite having normal renal function. Other risk factors for systemic absorption of oral vancomycin need to be evaluated in the literature, including severity of disease and underlying gastrointestinal processes.